PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy (PRO-PAS)
Condition(s):Peripheral Atherosclerotic DiseaseLast Updated:February 8, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Peripheral Atherosclerotic DiseaseLast Updated:February 8, 2024Recruiting
Condition(s):PreeclampsiaLast Updated:January 11, 2024Not yet recruiting
Condition(s):Coronary Artery Disease; DepressionLast Updated:April 20, 2023Recruiting
Condition(s):Coronary Artery EctasiaLast Updated:February 8, 2023Not yet recruiting
Condition(s):Unruptured Cerebral AneurysmLast Updated:May 6, 2023Recruiting
Condition(s):HIVLast Updated:October 16, 2023Recruiting
Condition(s):Coronary Artery Disease; Atherosclerosis, CoronaryLast Updated:March 20, 2024Recruiting
Condition(s):Left Atrial Appendage Closure; Thrombosis; Stroke; TIA; BleedingLast Updated:December 22, 2023Recruiting
Condition(s):Paediatric StrokeLast Updated:January 9, 2024Recruiting
Condition(s):Tuberculous MeningitisLast Updated:December 21, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.